Medsenic

After a torrid year that began with the late-stage failure of its knee osteoarthritis program, Bone Therapeutics SA hopes to have secured its survival through a reverse merger with France's Medseni

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk, Flagship Hope Combined Ef

Incyte Corporation is looking to broaden its presence in the market for chronic graft-versus-host disease (cGVHD) therapies with a global deal to develop and commercialize Syndax Pharmaceuticals, In